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ABSTRACT
Background: A 47-year-old Japanese woman was suffering from dermatomyositis with progressive interstitial
pneumonia, which was resistant to treatment with prednisolone (Pred) and cyclosporine A (CsA). Unfortu-
nately, the opportunistic infection and steroid psychosis made therapeutic intervention using additional im-
munosuppressive drugs problematic. To overcome these difficulties, we created a regimen of intravenous gam-
maglobulin (IVIG) and cyclophosphamide (CPM) for the treatment of this patient.
Methods: For the simultaneous treatment, IVIG-CPM was added to PredCsA by means of infusion of IVIG on
five consecutive days per month, followed by CPM infusion on the ninth day after the last IVIG administration.
The treatment was repeated for four months.
Results: This regimen induced almost full remission without exacerbation of the opportunistic infection or
mental disturbance.
Conclusions: The outcome reported here suggests that the combination therapy of PredCsA and IVIG-CPM
appears to be useful for the treatment of dermatomyositis with pulmonary, infectious and mental complications.
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INTRODUCTION
Dermatomyositis (DM) is associated with high mor-
bidity and mortality rates, primarily related to muscle
weakness, cardiac and lung impairment, as well as in-
fections. Many modes of intervention are available for
the treatment on this condition including corticoster-
oids , 1 immunosuppressive drugs such as CPM, 2-4
IVIG therapy,5-7 and plasmapheresis.8 Although com-
binations of these therapeutic interventions are often
adopted for intractable cases of this disease,9,10 the
relatively frequent occurrence of complications con-
sisting of opportunistic infection and steroid psycho-
sis have made treatment with additional immunosup-
pressive medications problematic. Here we describe
our experience with a combination treatment regi-
men of IVIG and CPM in a patient with DM, whose
course of therapy was hampered by complications.
CLINICAL SUMMARY
A 47-year-old woman presented with complaints of
easy fatiguability and muscle weakness causing diffi-
culties especially when climbing stairs. These com-
plaints had developed in conjunction with a DM-
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Fig. 1 Scheme of clinical course in this case. BMS, betamethasone; Pred, prednisolone; CsA, cyclosporine A; CPM, cy-
clophosphamide; IVIG, intravenous gammaglobulin.
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associated rash. The patient also reported episodes of
clinical depression following administration of be-
tamethasone (BMS) for DM.
DM had been diagnosed in 2002, when the patient
was 46, based on the presence of a characteristic der-
matitis, including a heliotrope rash, Gottron papules,
and poikiloderma, which was accompanied by proxi-
mal muscle weakness and elevated muscle-derived
enzyme levels . Treatment following diagnosis con-
sisted of 3 mgday of BMS and topical treatment .
However, the skin continued to show signs of DM
and muscle weakness abated only occasionally.
Moreover , steroid psychosis developed after about
four months of BMS treatment.
When the patient visited our outpatient clinic for
consultation, she was suffering from DM-associated
rash, proximal muscle weakness, acute respiratory
distress, and a mental disorder. These symptoms sig-
nificantly interfered with the activities of her daily life.
Laboratory examination findings showed an ele-
vated aldolase level of 36.2 UL (normal, < 7.2 UL),
anti-nuclear antibodies (homogenous, × 40), and an
elevated KL-6 level of 944 Uml (normal, < 500 Uml).
Magnetic resonance imaging (MRI) analysis showed
inflammation of the quadriceps femoris muscle, and
computed tomographic (CT) scan of the lung signs of
non-specific interstitial pneumonia . On the other
hand, diagnostic imaging analysis indicated no inter-
nal malignancy. The use of Pred instead of BMS was
recommended, and if the response was inadequate, of
oral CsA.
On admission, BMS was switched to 30 mgday of
Pred and 100 mgday of CsA for the first 21 days. Al-
though steroid psychosis was suppressed by admini-
stration of paroxetine, exacerbation of muscle weak-
ness, DM-associated rash, and interstitial shadows on
the lungs were observed, as well as dyspnea accom-
panying a daily reduction in oxygen partial pressure
(PaO2). Furthermore, cytomegalovirus (CMV) infec-
tion was confirmed by immunological staining of leu-
kocytes by using the monoclonal antibody HRP-C7.
Ophthalmoscopic examination disclosed some small
white punctate lesions resembling cotton-wool spots
in the macular area of both eyes, which is thought to
be the earliest sign of CMV retinitis. These lesions
showed regression in response to 7.5 mgkg of ganci-
clovir per day. There was recurrence of CMV retinitis
signs after withdrawal of ganciclovir infusion , but
these signs began to regress after ganciclovir infu-
sion was started. However, respiratory symptoms and
signs were not improved by ganciclovir infusion. The
absence of other opportunistic infections clearly indi-
cated that this progressive interstitial pneumonia was
caused by the exacerbation of DM. It seemed advis-
able to treat the primary disease with additional im-
munosuppressive drugs such as methylprednisolone
pulse therapy or CPM, but complications from oppor-
tunistic infection and steroid-induced depression
made the application of such treatments problematic.
The efficacy of IVIG for DM and opportunistic infec-
tions has been demonstrated, but not for interstitial
pneumonia. In view of these problems, simultaneous
treatment with IVIG-CPM was added to PredCsA
treatment. IVIG infusion (4 gkg body weightday)6
was performed on five consecutive days per month,
followed by CPM infusion at 500 mgday, equivalent
to about 10 mgkg body weight,4 on the ninth day fol-
lowing the last IVIG administration. From the first
month of treatment, the clinical status and the respi-
ratory symptoms gradually recovered together with
improvement in ALD and PaO2 values (Fig. 1). No
new major side effects were observed during the regi-
men.
The patient was given three courses of the regimen
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Fig. 2 CT scan of the lung. (A) before combination therapy, and (B) after the completion of al combina-
tion therapeutic courses.
of IVIGCPM infusion over four months and after all
courses were completed, marked improvements de-
tected in clinical symptoms and laboratory findings,
and observed on CT scans or MRI images were con-
firmed (Figs. 1,2). For 8 months after the final discon-
tinuation of this regime, the patient’s condition has
remained good with the administration of 17.5 mg
day of Pred and 100 mgday of CsA.
PATHOLOGICAL FINDINGS
A skin biopsy confirmed the diagnosis of DM by
demonstrating characteristic interface dermatitis with
mucin deposition (data not shown).
DISCUSSION
The most effective treatment of DM is still a matter of
debate . It has been frequently reported that corti-
costeroids constitute the mainstay of the treatment
with IVIG and other immunosuppressants added for
difficult cases. However, it has recently been pointed
out that these immunosuppressive medications may
be implicated in the apparent increase in the fre-
quency of opportunistic infections. Isabelle et al.,11 in
a study of 156 consecutive polymyositis (PM)DM
patients, reported a prevalence of opportunistic infec-
tions of 11.5%, and that the mean daily dose of ster-
oids was higher in patients with opportunistic infec-
tions than for those without (57.3 and 26.6 mg, re-
spectively). Opportunistic infection occurred in 62.5%
of cases during the first year following PMDM diag-
nosis. Although the majority of patients may receive
high doses of steroids during this period, 12.5% of
PMDM patients had not been exposed to steroids at
the onset of opportunistic infections. These findings
indicate that immune system dysfunction due to PM
DM itself may lead to elevated susceptibility to oppor-
tunistic infections. IVIG concentrates were originally
developed as a replacement therapy for individuals
with primary deficiencies of the immune system .
However, recent studies have demonstrated the abil-
ity of IVIG to prevent and possibly treat infections in
patients with secondary immune deficiencies . IVIG
have additional beneficial effects , especially on the
skin and muscle manifestations of DM. In view of
these findings, IVIG treatment is assumed to be bene-
ficial for the symptoms and complications associated
with DM. On the other hand, the efficacy of IVIG
treatment for interstitial pneumonia with DM is still
controversial. Interstitial lung disease (ILD) is a well-
recognized manifestation of PMDM, and previous
studies have reported a prevalence of interstitial lung
disease ranging from 10% to more than 50%.12 Pro-
gressive ILD is distinguished from the nonprogres-
sive version by extensive areas of ground-glass opac-
ity on high-resolution computed tomography (HRCT)
and by bronchoalveolar lavage (BAL) neutrophilia.12
While BAL of our patient was not examined , the
HRCT scan showed extensive diffuse areas of bilat-
eral ground-glass and reticular opacities, and the ab-
normalities involved both the central and peripheral
lung zones. Furthermore, arterial blood gas analysis
in room air indicated daily hypoxemic deterioration.
Intravenous CPM pulse therapy is known to be useful
for the treatment of progressive ILD.4,13,14 For our pa-
tient, too, intravenous CPM pulse therapy gradually
led to improvement in respiratory symptoms, while
application of Pred, CsA, and IVIG did not stop the
progression of ILD. It was even more remarkable that
no relapse of CMV retinitis was observed after simul-
taneous treatment with IVIG-CPM. In the past, effi-
cacy of treatment with IVIG and CPM in DMPM has
been disputed. There are two articles which describe
a treatment by IVIG together with low-dose oral ad-
ministration of CPM in DMPM.15,16 Chang et al.,16
reported that oral administration of CPM (2.2 mg
kg ) improved the clinical manifestations of IVIG-
resistant Evan’s syndrome associated with DM. But
there have been no reports which mention simultane-
ous treatment with IVIG and intravenous pulse-CPM.
Our case suggests that the newly constructed regi-
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men of IVIG and CPM may produce low-risk im-
provements in the symptoms of Pred- and CsA- resis-
tant DM associated with progressive ILD . At the
same time, Pred and CsA are effective for the mainte-
nance of a good overall condition of the patient. It can
therefore be assumed that the synergistic application
of these treatments may result in a better therapeutic
effect.
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